De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

Xiuchun Chen, Dechuang Jiao, Jianghua Qiao, Chengzheng Wang, Xianfu Sun, Zhen-Duo Lu, Lianfang Li, Chong-Jian Zhang, Min Yan, Ya Wei, Bo Chen, Yue-Qing Feng, Miao Deng, Mingde Ma, Jennifer K Plichta, You-Wen He, Zhenzhen Liu